Definium Therapeutics achieves clinical milestones with smaller-than-expected third-quarter loss
DFTX Definium Therapeutics Inc
$34.64 -2.12%
View chart & analysis → - 1Definium Therapeutics Inc reported a third-quarter diluted net loss per share of $0.46, beating the expected loss of $0.55 by 16.4%.
- 2Definium Therapeutics Inc secured positive topline results from the Phase 3 Voyage and Panorama studies of DT120 ODT.
- 3The FDA granted Breakthrough Therapy Designation for major depressive disorder.
So what's the key point?
Definium Therapeutics Inc recorded a smaller loss than expected and obtained good results from drug trials. The loss was less than what experts predicted and the company received a treatment designation, which is positive news for the company.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.